Needham Maintains Buy on Revolution Medicines, Raises Price Target to $35
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia maintains a Buy rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $31 to $35.
August 04, 2023 | 10:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst maintains a Buy rating on Revolution Medicines and raises the price target from $31 to $35.
The raised price target by Needham analyst indicates a positive outlook for the company. This could potentially lead to an increase in the stock price in the short term as it signals confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100